Clinical Trial Design: Statistical Options/Challenges Panel Discussion

First International Summit on Interventional Pharmacoeconomics

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Welcome and Introduction to Vi3C

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

Mark J. Ratain, MD, of the University of Chicago, talks about why ibrutinib—which can lead to cardiotoxicities—should be studied at a lower dose for patients with chronic lymphocytic leukemia. Data suggest a reduced dose may prevent dose interruption due to adverse events and may have a better therapeutic index.

David A. Hyman, MD, JD, on Inclusive Shared Savings

Cost of Care

Health-Care Policy

The ASCO Post Staff

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of treatments that improve survival and quality of life.

Oct

Today In Oncology

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Related Videos

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Welcome and Introduction to Vi3C

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

David A. Hyman, MD, JD, on Inclusive Shared Savings

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Study Examines Use of External-Beam Radiotherapy as a Bridging Therapy for Patients With HCC Awaiting Transplant

Phase III Trial Evaluates Efficacy of Total Androgen Suppression Plus Dose-Escalated Radiotherapy for Patients With Intermediate-Risk Prostate Cancer

FOCUS4-C Trial: Hint of Activity Reported With Adavosertib in Metastatic Colorectal Cancer

Addition of Vincristine, Topotecan, and Cyclophosphamide to Five-Drug Interval-Compressed Chemotherapy for Ewing Sarcoma

Baseline Health-Related Quality of Life and Outcomes in Patients With Advanced Cancer